Shanghai Pharmaceuticals’ Ticagrelor tablets have been approved for marketing by the US FDA.
November 7, 2025
Source: drugdu
71
Beijing Business Daily (Reporter Wang Yinhao and Song Yuying) - On November 6th, Shanghai Pharmaceuticals...The company announced that its subsidiary, Changzhou Pharmaceutical Factory Co., Ltd., received a notification from the U.S. Food and Drug Administration (FDA) that its Abbreviated New Drug Application (US Generic Drug Application) for ticagrelor tablets has been finally approved for marketing.
The announcement indicates that ticagrelor tablets are used for patients with acute coronary syndrome, including those receiving drug therapy and percutaneous coronary intervention, to reduce the incidence of thrombotic cardiovascular events. The original drug was launched in the United States in 2011.
https://finance.eastmoney.com/a/202511063557185324.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
